Latest updates on Remdesivir – COVID-19 vaccine

Hetero Healthcare Ltd. have stated through their company website that they are supplying 60000 vials of the generic version of Remdesivir injection in India from 13th July to 20th July, named “Covifor”, which is the first-ever generic brand of Remdesivir, the only drug approved by the Food and Drug Administration of United States  (USFDA) for Emergency Use Authorization (EUA) treatment of hospitalized covid-19 patients.

Covifor is available in 100 mg vials, and needs to be administered intravenously under the supervision of a registered medical practitioner in either a hospital or a critical care setting.

Out of the mentioned 60000 vials, Maharashtra, the most severely affected state will be getting highest quantity, 12500, followed by Delhi, Telangana, Tamil Nadu, Gujarat, Karnataka and Andhra Pradesh, who will be getting, 10000, 7500, 6000, 3000 and 2000 respectively, whereas the rest of India will get 10000 injections.

As at 11:00 a.m. on Wednesday, the information available on the company’s official website stated that Hetero has a supplied 14,502 vials to Telangana, as well as to 166 hospitals in Maharashtra and 53 hospitals in Delhi.

Meanwhile, another Pharma Giant, Dr. Reddy’s Laboratories Ltd, which also holds a non-exclusive licensing agreement with the creator of Remdesivir – Gilead Sciences Inc. for manufacturing and selling the mentioned drug in 127 countries including India, is yet to receive approval from the DCGI to start their manufacturing process in India.

The maximum retail price for each 100 MG vial antiviral drug Covifor (remdesivir) is Rs. 5,400 Recently, the developer of Remdesivir, Gilead Sciences have reported data from their comparative analysis of phase 3 clinical trials, that the drug has demonstrated improvement in clinical recovery and a reduction of 62 per cent in the risk of death when compared to standard care protocols.